Is elastography needed for diagnosing cACLD and stratifying CSPH risk?
Georg Semmler(University of Southern Denmark), Mattias Mandorfer(Medical University of Vienna), Benedikt Simbrunner(Austrian Academy of Sciences), Lukas Hartl(Medical University of Vienna), Katharina Stopfer(Medical University of Vienna), Bernhard Scheiner(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), Benedikt Hofer(Austrian Academy of Sciences), Daniela Neumayer(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Lorenz Balcar(Medical University of Vienna), L. Fritz(Medical University of Vienna), Jurij Maurer(Medical University of Vienna), Robin Szymanski(Medical University of Vienna), Anna Schedlbauer(Medical University of Vienna), Michael Schwarz(Medical University of Vienna)
Cited by 1
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561